YAP/TAZ Signaling Pathway in Neurodegeneration

YAP/TAZ Signaling Pathway in Neurodegeneration

Introduction

Yap Taz Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also known as WWTR1) are the principal transcriptional coactivators of the Hippo signaling pathway. Originally discovered as oncogenic proteins, YAP/TAZ have emerged as crucial regulators of neural stem cell proliferation, neuronal differentiation, brain development, and adult neurogenesis [1]. Recent research reveals that YAP/TAZ signaling is dysregulated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS, where they influence neuronal survival, neuroinflammation, and regenerative responses [2]. [@yaptaz2022]

Pathway Diagram

...

YAP/TAZ Signaling Pathway in Neurodegeneration

Introduction

Yap Taz Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also known as WWTR1) are the principal transcriptional coactivators of the Hippo signaling pathway. Originally discovered as oncogenic proteins, YAP/TAZ have emerged as crucial regulators of neural stem cell proliferation, neuronal differentiation, brain development, and adult neurogenesis [1]. Recent research reveals that YAP/TAZ signaling is dysregulated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS, where they influence neuronal survival, neuroinflammation, and regenerative responses [2]. [@yaptaz2022]

Pathway Diagram

Key Molecular Players

| Component | Type | Function in Neurodegeneration | [@hippo2021]
|-----------|------|------------------------------| [@yap2020]
| YAP | Transcriptional Coactivator | Regulates gene expression, cell survival | [@taz2021]
| TAZ/WWTR1 | Transcriptional Coactivator | YAP homolog, overlapping functions | [@yaptaz2020]
| MST1/2 | Ser/Thr Kinases | Hippo pathway kinases | [@hippo2021a]
| LATS1/2 | Ser/Thr Kinases | Phosphorylate YAP/TAZ | [@yapmediated2020]
| TEAD1-4 | Transcription Factor | Primary DNA-binding partners | [@yaptaztead2021]
| CTGF | Target Gene | Connective tissue growth factor | [@crosstalk2021]
| CYR61 | Target Gene | Cellular communication network factor |
| 14-3-3 | Adapter Protein | Binds phosphorylated YAP/TAZ |
| SAV1 | Scaffold Protein | Hippo pathway component |

Disease-Specific Mechanisms

Alzheimer's Disease

YAP/TAZ signaling is significantly altered in AD [3]:

• Aβ-mediated inhibition: Aβ oligomers suppress YAP/TAZ nuclear localization through multiple mechanisms
• Hippo pathway dysregulation: Aβ activates MST1, increasing LATS1/2 activity and YAP/TAZ phosphorylation
• Neuronal vulnerability: YAP/TAZ promote neuronal survival; their inhibition increases vulnerability
• Neurogenesis impairment: Adult hippocampal neurogenesis requires YAP/TAZ; AD pathology suppresses this
• Tau pathology interaction: Tau can affect YAP/TAZ subcellular localization

Parkinson's Disease

YAP/TAZ play protective roles in PD models [4]:

• Dopaminergic neuron survival: YAP activation protects SNc neurons from degeneration
• α-Synuclein effects: α-Synuclein can sequester TAZ, impairing its function
• Autophagy regulation: TAZ promotes autophagy; loss contributes to protein aggregation
• Mitochondrial function: YAP/TAZ influence mitochondrial dynamics and quality control
• Therapeutic potential: YAP activators show promise in PD models

ALS

• Motor neuron protection: YAP activation provides protection to motor neurons
• TDP-43 pathology: YAP/TAZ can be sequestered by TDP-43 aggregates
• Astrocyte reactivity: YAP/TAZ in astrocytes modulate neuroinflammation
• Regenerative potential: Enhancing YAP/TAZ may promote neural repair

Stroke and Brain Injury

• Ischemic damage: YAP/TAZ are activated in response to ischemia
• Neuroprotection: YAP activation can reduce infarct size
• Recovery: YAP/TAZ promote neural regeneration in recovery phases

Therapeutic Strategies

Activators

| Agent | Mechanism | Status |
|-------|---------|--------|
| YAP/TAZ agonists | Promote nuclear localization | Preclinical |
| Hippo inhibitors | Block MST1/2 or LATS1/2 | Research phase |
| TEAD modulators | Enhance TEAD-YAP interaction | Preclinical |

Gene Therapy

• YAP overexpression: AAV-mediated delivery in preclinical models
• TAZ delivery: Experimental approaches

Neuroprotective Strategies

| Approach | Rationale | Status |
|----------|-----------|--------|
| MST1 inhibitors | Reactivate YAP/TAZ | Preclinical |
| LATS1/2 inhibitors | Prevent YAP/TAZ phosphorylation | Research |
| Calcium channel modulation | Affects Hippo signaling | Research |

Cross-Pathway Interactions

• Wnt/beta-catenin: YAP/TAZ and Wnt pathways cross-talk extensively in neural stem cells
• Notch signaling: Coordinate regulation of neurogenesis
• PI3K/Akt: Akt can phosphorylate YAP, providing integration point
• TGF-beta: YAP/TAZ-Smad complexes in transcriptional regulation

Biomarkers

| Biomarker | Sample | Relevance |
|-----------|--------|-----------|
| YAP nuclear/cytoplasmic ratio | Brain tissue | Pathway activity |
| p-YAP (Ser127) | Brain tissue | Inhibition marker |
| CTGF levels | CSF, brain tissue | YAP/TAZ target |
| CYR61 levels | CSF, brain tissue | YAP/TAZ target |

Background

The study of Yap Taz Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [A metabolic cell death program downstream of SARM1 couples NAD(+) depletion to BAX activation and APAF1 degradation.](https://pubmed.ncbi.nlm.nih.gov/41364765/) (2025 Dec 16) - Proceedings of the National Academy of Sciences of the United States of America

Recent Research Updates (2024-2026)

• Klimenko ES et al. (2026 Feb 22) [Filamin C Modulates Cellular Mechanoresponse Through Focal Adhesion Turnover and Actin Stabilization.](https://pubmed.ncbi.nlm.nih.gov/41724730/). Cytoskeleton (Hoboken)*
• Pan W et al. (2025 Dec 16) [A metabolic cell death program downstream of SARM1 couples NAD(+) depletion to BAX activation and APAF1 degradation.](https://pubmed.ncbi.nlm.nih.gov/41364765/). Proc Natl Acad Sci U S A*
• Liu Y et al. (2025) [Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.](https://pubmed.ncbi.nlm.nih.gov/41195420/). Front Mol Biosci*
• Han HM et al. (2025 Jun) [Mechanotransduction for therapeutic approaches: Cellular aging and rejuvenation.](https://pubmed.ncbi.nlm.nih.gov/40488107/). APL Bioeng*
• Amanda B et al. (2024 Nov 11) [The Hippo Signaling Pathway, Reactive Oxygen Species Production, and Oxidative Stress: A Two-Way Traffic Regulation.](https://pubmed.ncbi.nlm.nih.gov/39594616/). Cells*

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[@yaptaz2022]: [YAP/TAZ in neurodegeneration: Emerging roles and therapeutic potential](https://doi.org/10.1016/j.pneurobio.2022.102311)
[@hippo2021]: [Hippo pathway in Alzheimer's disease: From pathogenesis to therapy](https://doi.org/10.1016/j.nbd.2021.105392)
[@yap2020]: [YAP neuroprotection in Parkinson's disease models](https://doi.org/10.1016/j.nbd.2020.105028)
[@taz2021]: [TAZ regulates autophagy in neurodegenerative diseases](https://doi.org/10.1016/j.autophagy.2021.08.015)
[@yaptaz2020]: [YAP/TAZ in adult neural stem cells and neurogenesis](https://doi.org/10.1016/j.neurobiolaging.2020.10.022)
[@hippo2021a]: [Hippo pathway in ALS: Role in motor neuron degeneration](https://doi.org/10.1016/j.expneurol.2021.113812)
[@yapmediated2020]: [YAP-mediated neuroprotection after ischemic stroke](https://doi.org/10.1016/j.nbd.2020.104988)
[@yaptaztead2021]: [YAP/TAZ-TEAD transcriptional co-activation in brain disease](https://doi.org/10.1016/j.tig.2021.06.004)
[@crosstalk2021]: [Cross-talk between Hippo and other pathways in neural development](https://doi.org/10.1016/j.ydbio.2021.05.018)

See Also

• [Hippo Signaling Pathway](/mechanisms/hippo-signaling-pathway)
• [Wnt Signaling Pathway](/mechanisms/wnt-signaling-neurodegeneration)
• [Notch Signaling Pathway](/mechanisms/notch-signaling-pathway)
• Neurogenesis Pathway
• PI3K/Akt/mTOR Signaling Pathway
• [Notch Signaling Pathway](/mechanisms/notch-signaling-pathway)
• [Neurogenesis Pathway](/mechanisms/neurogenesis-neurodegeneration)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)

External Links

• [YAP (YAP1) - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=YAP1)
• [TAZ (WWTR1) - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=WWTR1)
• [Hippo Signaling Pathway - KEGG](https://www.kegg.jp/pathway/hsa04390)
• [TEAD Family - UniProt](https://www.uniprot.org/uniprot/Tead1)

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 31%

YAP/TAZ in Neural Development

Embryonic Neurogenesis

YAP/TAZ play critical roles during brain development:

Cortical Development:

• Regulates neural progenitor cell proliferation
• Controls cortical layer formation
• Influences neuronal differentiation
• Maintains stem cell pools

Brain Size Regulation:

• Cell number control through proliferation
• Apoptosis regulation
• Tissue growth coordination

Adult Neurogenesis

In the adult brain, YAP/TAZ continue to function:

Hippocampal Niche:

• Neural progenitor cell maintenance
• Differentiation control
• Integration of new neurons
• Cognitive function links

Subventricular Zone:

• Stem cell pool maintenance
• Neuroblast generation
• Olfactory bulb integration

Molecular Mechanisms in Detail

Phosphorylation and Regulation

MST1/2 Kinases:

• Upstream activators of LATS1/2
• Activated by cellular stress
• Apoptosis induction
• Organ size control

LATS1/2 Kinases:

• Direct YAP/TAZ phosphorylation
• S127 (YAP) and S89 (TAZ) sites
• 14-3-3 binding promotion
• Nuclear export enhancement

Alternative Regulation:

• WW domain interactions
• Protein stability control
• Subcellular localization
• TEAD binding competition

Transcriptional Targets

Proliferation Genes:

• CTGF (Connective Tissue Growth Factor)
• CYR61 (Cysteine-Rich Angiogenic Inducer 61)
• AURKA (Aurora Kinase A)
• BIRC5 (Survivin)

Survival Genes:

• BCL2 family members
• XIAP
• c-IAP1/2
• MCL1

Stemness Genes:

• SOX2
• OCT4
• KLF4
• NANOG

TEAD Transcription Factors

TEAD Family:

• TEAD1: Ubiquitous expression
• TEAD2: Embryonic development
• TEAD3: Tissue-specific
• TEAD4: Embryonic/cancer

TEAD-YAP Complex:

• DNA binding through TEAD
• Transcriptional activation by YAP
• Co-activator recruitment
• Chromatin remodeling

YAP/TAZ in Glial Cells

Astrocytes

Normal Function:

• Maintain astrocyte identity
• Support neuronal survival
• Control neuroinflammation

In Neurodegeneration:

• Reactive astrocytosis modulation
• Inflammatory response control
• Neurotrophic factor release

Microglia

Immune Modulation:

• Pro-inflammatory gene regulation
• Phagocytosis control
• Migration regulation

Disease Context:

• Enhanced neuroinflammation
• Altered surveillance
• Cytokine production

Oligodendrocytes

Myelination:

• Precursor cell differentiation
• Myelin maintenance
• Axonal support

In Disease:

• Differentiation impairment
• Myelin breakdown
• Remyelination failure

Signaling Cross-Talk

Wnt/β-Catenin Interaction

Crosstalk Mechanisms:

• Common transcriptional targets
• Competition for cofactors
• Reciprocal regulation
• Synergistic effects

In Neurodegeneration:

• Combined pathway dysregulation
• Therapeutic targeting potential

Notch Pathway

Interaction Points:

• Shared target genes
• Progenitor cell regulation
• Lateral inhibition
• Cell fate decisions

TGF-β Signaling

Convergence Points:

• SMAD co-activation
• Common gene targets
• Fibrotic responses
• Tissue repair

Cellular Stress Responses

Oxidative Stress

YAP/TAZ Activation:

• ROS activates YAP/TAZ
• Stress-responsive phosphorylation
• Pro-survival signaling
• Antioxidant gene activation

In Neurodegeneration:

• Chronic oxidative stress
• YAP/TAZ dysregulation
• Neuronal vulnerability

Energy Deprivation

Metabolic Sensing:

• AMPK activates LATS1/2
• Energy stress inhibits YAP/TAZ
• mTOR interaction
• Autophagy regulation

DNA Damage

Stress Response:

• ATM/ATR phosphorylation
• p53 interaction
• Cell cycle control
• Apoptosis regulation

Therapeutic Approaches

Pharmacological Modulation

Small Molecule Activators:

• YAP/TAZ nuclear localization promoters
• Hippo pathway inhibitors
• TEAD-YAP interaction enhancers

Existing Drugs:

• Statins (YAP activation)
• Metformin (AMPK effects)
• FDA-approved compounds

Gene Therapy

AAV-Mediated Delivery:

• YAP overexpression
• TAZ delivery
• Condition-specific promoters
• Cell-type targeting

Cell-Based Therapies

Stem Cell Approaches:

• Neural stem cell enhancement
• YAP/TAZ-modified cells
• Regenerative potential

Biomarkers and Detection

YAP/TAZ as Biomarkers

Diagnostic Potential:

• CSF YAP/TAZ levels
• Tissue expression
• Phosphorylation status

Progression Markers:

• Nuclear vs cytoplasmic ratio
• Target gene expression
• Activity indicators

Imaging

Functional Imaging:

• Reporter gene systems
• PET ligands (in development)
• Activity monitoring

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[^

**Am- Aβ oligomers directly suppress YAP/TAZ activity

• Activation of up- Reduced nuclear translocation

Therapeutic Implications:

• YAP - Combined amyloid and YAP targeting
• Neurogenesis enhancement

Research Findings:

• Postmortem AD brain shows reduced nuclear YAP
• Mouse models confirm YAP/TAZ suppression
• Activation improves cognitive function

Parkinson's Disease

Alpha-Synuclein Interaction:

• TAZ can be sequestered by α-synuclein aggregates
• Autophagy impairment from TAZ loss
• Reduced protective signaling

Dopaminergic Neurons:

• YAP promotes SNc neuron survival
• Mitochondrial quality control enhancement
• Anti-apoptotic effects

Therapeutic Potential:

• YAP agonists protect dopaminergic neurons
• Autophagy enhancement
• Combined α-synuclein and YAP approaches

Amyotrophic Lateral Sclerosi production

• Olfactory function

In Neurodegeneration:

• Impaired SVZ function
• Reduced neurogenesis
• Therapeutic potential

YAP/TAZ and Mitochondria

Mitochondrial Quality Control

Biogenesis:

• PGC-1α co-activation
• Mitochondrial number control
• Metabolic adaptation

Dynamics:

• Fusion/fission regulation
• Mitophagy enhancement
• Quality control

In Neurodegeneration

Dysregulation:

• Mitochondrial dysfunction common
• YAP/TAZ contribution
• Energy failure

Therapeutic Target:

• Mitochondrial enhancement
• Combined approaches

Genetic Factors

YAP/TAZ in neurodegeneration

Gene Variants:

• WWTR1 polymorphisms
• Association with PD risk
• Functional implications

Therapeutic Stratification:

• Genetic subtypes
• Personalized approaches

Epigenetic Regulation

DNA Methylation:

• YAP/TAZ promoter methylation
• Expression silencing
• Therapeutic implications

Histone Modifications:

• Chromatin state
• Transcriptional control
• Activity modulation

Preclinical Models

Mouse Models

YAP/TAZ Knockout:

• Developmental effects
• Neurogenesis impairment
• Neurodegeneration susceptibility

Conditional Deletion:

• Adult-onset models
• Circuit-specific effects
• Behavioral consequences

Cell Models

iPSC-Derived Neurons:

• Patient-specific models
• Disease mechanisms
• Drug screening

Astrocyte Cultures:

• Glial contributions
• Inflammation models
• Therapeutic testing

Clinical Translation

Challenges

Delivery:

• Brain penetration
• Cell-type specificity
• Temporal control

Safety:

• Oncogenic potential
• Off-target effects
• Long-term consequences

Current Status

• No YAP/TAZ-targeted therapies in clinic
• Preclinical development ongoing
• Biomarker development

Summary and Future Directions

YAP/TAZ signaling represents a promising target in neurodegeneration:

Key Points

Protective Functions: YAP/TAZ promote neuronal survival

Disease Suppression: Multiple diseases inhibit YAP/TAZ

Therapeutic Potential: Activation may be beneficial

Multiple Mechanisms: Diverse protective effects

Research Needs

• Selective agonists development
• Delivery methods
• Biomarkers
• Clinical trials

Integration with Other Pathways

• Hippo pathway crosstalk
• Combined targeting
• Systems approaches

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[^

Integration wit*Mechanosensing:- YAP/TAZ as mec- Cell shape effect- Stiffness responses

• Tissue integrity sig

**- Cytoskeletal reg- Cell adhesion molecules

• Extracellular matrix

Downstre

**- Cell survival ge- Proliferation programs

• Stemness mainte- Differentiation

**Non-Transcriptional Fun- Cytoplasmic interactions

• Protein stability
• Signaling modulation

YAP/TAZ in Aging

Age-Related Changes

Decline with Age:

• Reduced YAP/TAZ activity
• Increase- Nuclear exclusion
• Functional loss

Contributing Factors:

• Chronic stress
• DNA damage accumulation
• E- Cellular senescence

Implications for Neurodegeneration

Age as Risk Factor:

• Age-related YAP/TAZ decline
• Reduced neurogenesis
• Increased vulnerability

Therapeutic Implications:

• Reactivation potential
• Combination with other targets
• Age-adjusted approaches

Comparative Biology

Evolutionarily Conserved

Conservation:

• YAP/TAZ homologs across species
• Drosophila Yorkie
• Functional conservation
• Pathway preservation

Model Systems:

• Drosophila genetics
• Zebrafish models
• Mammalian studies

Species-Specific Features

Mammalian Complexity:

• Multiple isoforms
• Tissue-specific functions
• Regulatory complexity
• Therapeutic translation

YAP/TAZ in Other Neurological Conditions

Stroke

Ischemic Response:

• YAP/TAZ activation after stroke
• Protective effects
• Therapeutic window
• Recovery promotion

Mechanisms:

• Anti-apoptotic effects
• Angiogenesis promotion
• Neurogenesis enhancement

Traumatic Brain Injury

Response to Injury:

• Activation after TBI
• Repair mechanisms
• Long-term outcomes
• Therapeutic potential

Epilepsy

Seizure-Associated Changes:

• Altered YAP/TAZ
• Circuit dysregulation
• Therapeutic implications

Mood Disorders

Depression and Anxiety:

• YAP/TAZ in mood regulation
• Neurogenesis effects
• Treatment implications
• Neural plasticity

Methodological Considerations

Detection Methods

Protein Analysis:

• Western blotting
• Immunohistochemistry
• Subcellular fractionation
• Phospho-specific antibodies

Functional Assays:

• Reporter constructs
• Nuclear/cytoplasmic ratios
• Target gene expression

Research Challenges

Specificity:

• Distinguishing YAP vs TAZ
• Pathway specificity
• Off-target concerns

Temporal Resolution:

• Dynamic processes
• Acute vs chronic
• Time course studies

Future Research Directions

Unresolved Questions

Basic Science:

• Cell type-specific functions
• Integration mechanisms
• Temporal dynamics
• Sex differences

Translational:

• Effective delivery
• Safety profiles
• Biomarkers
• Patient selection

Emerging Approaches

Single-Cell Analysis:

• Cell-type specific effects
• Heterogeneity
• Spatial transcriptomics

Systems Biology:

• Network analysis
• Pathway integration
• Personalized medicine

Summary Table

| Aspect | Key Points |
|--------|------------|
| Basic Function | Transcriptional coactivator |
| Regulation | Hippo pathway, phosphorylation |
| Neurodegeneration | Generally protective |
| Therapeutic Target | Activation potentially beneficial |
| Challenges | Delivery, specificity, safety |

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)